NewAmsterdam Pharma price target raised to $31 from $25 at RBC Capital
The Fly

NewAmsterdam Pharma price target raised to $31 from $25 at RBC Capital

RBC Capital raised the firm’s price target on NewAmsterdam Pharma to $31 from $25 and keeps an Outperform rating on the shares after its Q4 update. The company’s BROOKLYN and BROADWAY readouts remain on track for Q3 and Q4 of this year, and its PREVAIL study is looking to complete enrollment this quarter for a readout in 2026, the analyst tells investors in a research note. RBC adds that it remains confident in the likelihood of success for the phase 3 lipid lowering studies, and that the 40%-50% reductions in low-density lipoprotein can translate to highly meaningful cardiovascular benefits, unlocking a $1.3B U.S. opportunity.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on NAMS:

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App